Cancer. Agranulocytosis secondary to cancer chemotherapy
Conditions
Interventions
Intervention 1: Intervention group: Drug combination: Famotidine 40 mg, taken daily, for 3 days in each period + Loratadine 10 mg, taken daily, for 3 days in each period +
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patient has a malignant tumor regardless of the type of organ involved, which is a candidate for treatment with pegfilgrastim (PEG-G-CSF) according to the standard chemotherapy protocol and the course of chemotherapy is at least two cycles.
Exclusion criteria
Exclusion criteria: Contraindications for medications in each arm
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain score. Timepoint: The first, second and fourth days in two periods. Method of measurement: Questionnaire (Verbal Numerical Scale). | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: The first, second and fourth days in two periods. Method of measurement: Questionnaire: Fact-BP and EQ-5D.;Adverse events. Timepoint: The first, second and fourth days in two periods. Method of measurement: Common Terminology Criteria for Adverse Events (CTCAE). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParisa Jalali
Tehran University of Medical Sciences
Outcome results
None listed